Global Desmoid Tumors Market Size, Share, Trends, COVID-19 Impact & Growth Forecast Report - Segmented By Based on Drug Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Targeted Therapy Chemotherapy, Hormone Therapy, Others), Distribution Channel and Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Analysis from 2025 to 2033
Global Desmoid Tumors Market Report Summary
The global desmoid tumors market was valued at USD 2.90 billion in 2024, is estimated to reach USD 3.10 billion in 2025, and is projected to reach USD 5.28 billion by 2033, growing at a CAGR of 6.9% during 2025–2033. Market growth is driven by a robust pipeline of novel treatment options, rising adoption of advanced imaging technologies, and increasing awareness of rare tumor conditions. The development of targeted therapies, improved diagnostic capabilities, and expanding R&D investments are further accelerating market expansion. In addition, government funding, awareness campaigns, and improved access to specialized care are enhancing patient outcomes and supporting overall market growth.
Key Market Trends
- Growing focus on targeted therapies and novel drug approvals, offering higher efficacy and reduced side effects.
- Increasing adoption of advanced imaging technologies such as MRI and CT for early and accurate detection.
- Rising awareness of desmoid tumors among clinicians and patients, enhancing diagnosis and treatment rates.
- Expansion of telemedicine and remote diagnostics supporting long-term patient monitoring.
- Growing emphasis on research collaborations and clinical trials to accelerate the development of next-generation therapies.
Segmental Insights
- Based on drug type, the chemotherapy segment held the largest share of the global desmoid tumors market in 2024, driven by its wide clinical adoption, established treatment protocols, and strong demand among patients requiring systemic therapy.
- Based on distribution channel, online pharmacies captured a significant share in 2024, supported by rising digital adoption, convenience, and increased use of e-commerce platforms for chronic care medication refills..
Regional Insights
The global desmoid tumors market is experiencing steady expansion across major regions, supported by rising healthcare investments, clinical research advancements, and improved access to rare disease treatments.
- North America was the largest contributor in 2024, driven by high healthcare expenditure, strong diagnostic infrastructure, active clinical trials, and growing patient awareness. The U.S. leads the region due to its advanced oncology ecosystem and rising diagnosis rates.
- Europe accounted for a significant share of the global market, supported by strong rare disease research networks, robust regulatory frameworks, and increasing adoption of innovative therapies.
- Asia-Pacific is poised to witness the fastest growth, fueled by rising healthcare infrastructure development, growing awareness of rare tumors, and expanding access to advanced diagnostics and treatment options.
- Latin America and the Middle East & Africa show steady growth driven by improving healthcare access and increasing focus on oncology care.
Competitive Landscape
The global desmoid tumors market is characterized by the presence of established pharmaceutical companies and emerging biotechnology innovators focusing on advanced targeted therapies, improved diagnostic tools, and enhanced patient management solutions. Companies are prioritizing clinical trial expansion, regulatory approvals, and strategic partnerships to strengthen their portfolios and accelerate commercialization. Key players include Horizon Therapeutics, Strides Pharma, Teva Pharmaceutical Industries, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Natco Pharma, Lupin, Zydus Lifesciences, Mylan, Assertio Holdings, Mayne Pharma, Alembic Pharmaceuticals, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Iterion Therapeutics, Novartis, and Apotex.
Global Desmoid Tumors Market Size
The global desmoid tumors market size was valued at USD 2900 million in 2024 and is estimated to reach USD 5286.65 million by 2033 from USD 3100.10 million in 2025, registering a CAGR of 6.9% from 2025 to 2033.
MARKET DRIVERS
The robust pipeline of novel drugs for desmoid tumors primarily drives the growth of the desmoid tumors market. The robust pipeline of novel drugs indicates that researchers and pharmaceutical companies are actively investing in finding an effective treatment for desmoid tumors as new drugs are developed and approved. Patients have access to more diverse and potentially more effective treatment options. The development of novel drugs offers improved efficacy which could lead to better control of tumor growth, reduced side effects and it also improved the quality of life for patients with desmoid tumors. The development of novel drugs leads to interaction with the regulatory authorities, which can expedite the availability of innovative therapies for patients.
The rapid adoption of technological advancements in desmoid tumor treatment further fuels the market’s growth rate. The advancements lead to improved diagnosis and treatment efficiency. Advanced imaging technologies such as MRI, CT-scans can provide more accurate and detailed information about the size, location, and characteristics of the desmoid tumors that help in better treatment planning and monitoring. The advancements also led to identifying specific molecular targets within the desmoid tumors.
The growing awareness about desmoid tumors among people and healthcare professionals contributes to the global market growth. The rising awareness leads to better recognition of desmoid tumor symptoms among patients and healthcare professionals. Also, the rising government funding can support research efforts to understand the causes of desmoid tumors, help in the development of new treatments, and improve existing therapies. The awareness campaign can empower patients and their families by providing information and resources, which leads to improving patient care and treatment decision-making, and proper diagnosis, These factors contribute to the overall growth of the market during the forecast period. Factors such as the growing number of R&D activities around desmoid tumors and growing healthcare expenditure by the governments of various countries further propel the global market growth.
MARKET RESTRAINTS
The high cost of desmoid tumor treatment drugs and the side effects associated with chemotherapy and other desmoid tumor drugs are one of the major obstacles to the growth rate of the desmoid tumors market. People are continuously taking medication and therapy treatments, such as chemotherapy and radiation therapy, which can develop long-term side effects. These side effects can happen a year after treatment which is anticipated to hamper the overall growth of the market. Developing the drug for the treatment of desmoid tumors involves substantial research and development expenses, which can contribute to rising the cost of drugs; high drug prices can create a barrier to access for patients, especially for low and middle-income countries and for those individuals who have adequate insurance coverage, which is another major factor hindering the global market growth. Side effects associated with the drugs have a significant impact on patients' quality of life; these side effects often include nausea, hair loss, fatigue, and weakened immune system, and such adverse effects can lead to poor patient compliance with treatment, the global market growth.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| Segment covered | Based on Drug Type, Distribution Channel, and Region. |
| Various analyses covered | Global, Regional, Country Level Analysis, Segment Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTEL Analysis, Competitive Landscape. |
| Regions covered | North America, Europe, Asia-pacific, Latin America, the Middle East, and Africa. |
| Key Market Players | Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin, Zydus Lifesciences, Mylan N.V., Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, AYala-led Pharmaceuticals, and SpringWorks Therapeutics, Inc. |
SEGMENTAL ANALYSIS
By Drug Type Insights
The chemotherapy segment was the largest in the global market in 2024 and is anticipated to continue dominating the market during the forecast period. The growing cancer patient population worldwide and increasing preference for chemotherapy as a treatment option mainly drive the growth of the chemotherapy segment in the worldwide market.
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is anticipated to account for a substantial share of the global desmoid tumors market during the forecast period. These drugs can reduce pain and inflammation, and desmoid tumors can cause discomfort and pain due to their location and size. These drugs help to alleviate these symptoms and help improve the quality of life for patients, and give relief.
By Distribution Channel Insights
Based on the distribution channel, the online pharmacies segment is estimated to account for the major share of the worldwide market during the forecast period. The COVID-19 pandemic situation strengthened the digital commerce platform, and this has resulted in the increased adoption of online pharmacies for various medical needs. This trend is likely to continue in the coming years and propel the segmental growth.
The hospital segment is another major segment among all and is expected to account for a considerable share of the global market during the forecast period, owing to the growing demand for drugs for treatment and the increasing patient population visiting hospitals for treatment needs.
REGIONAL ANALYSIS
North America is the largest regional segment in the global desmoid tumors market and is expected to continue its leading position in the worldwide market throughout the forecast period. Factors such as the rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America drive the North American market growth. Technological advancements in imaging, such as MRI and CT scans, have enhanced the ability to detect and locate desmoid tumors. The U.S. is expected to hold the major share of the North American market during the forecast period, owing to the increasing aging population, rapid adoption of sedentary lifestyles, environmental exposures, and increasing patient population of desmoid tumors.
Europe is another noteworthy regional market for desmoid tumors and is estimated to hold a substantial share of the worldwide market during the forecast period. The growing healthcare expenditure, the presence of robust healthcare systems, improved access to specialized care, collaboration among European countries in medical research, and rising emphasis on rare disease research and orphan drug development majorly propel the growth of the desmoid tumors market in Europe.
The Asia-Pacific region is expected to witness the fastest CAGR in the global market during the forecast period. The growing patient population, growing healthcare investments and infrastructure development, and increasing awareness of rare diseases and access to healthcare primarily drive the growth of the desmoid tumors market in the Asia-Pacific region.
KEY MARKET PLAYERS
Some of the major players in the global desmoid tumors market.
- Horizon Therapeutics Plc
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Hikma Pharmaceuticals PLC
- Natco Pharma Ltd
- Lupin
- Zydus Lifesciences
- Mylan N.V.
- Assertio Holdings, Inc.
- Mayne Pharma Group Limited
- Alembic Pharmaceuticals Limited
- Aprazer
- AYala-led Pharmaceuticals
- SpringWorks Therapeutics, Inc.
- Iterion Therapeutics
- Novartis AG
- Apotex Inc.
RECENT MARKET DEVELOPMENTS
- In May 2022, Positive topline results from the double-blind placebo-controlled phase 3 DeFi trial (NCT03785964), which examined the use of nirogacestat as a therapy for adult patients with progressive desmoid tumors, were released by clinical-stage biopharmaceutical startup SpringWorks Therapeutics.
- In September 2022, according to an announcement by Ayala Pharmaceuticals, AL102 has been given a fast-track designation by the US Food and Drug Administration for the treatment of patients with developing desmoid tumours.
MARKET SEGMENTATION
This research report on the global desmoid tumors market has been segmented and sub-segmented based on the following categories.
By Drug Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
What is the desmoid tumors market?
The desmoid tumors market focuses on treatments, therapies, and diagnostics used for managing desmoid-type fibromatosis, a rare and locally aggressive soft-tissue tumor. The market includes pharmaceuticals, surgical procedures, radiation therapy, and targeted therapies.
What drives the growth of the desmoid tumors market?
Increasing awareness of rare diseases, advancements in targeted therapies, and rising research initiatives drive market growth. Improved diagnostic technologies also contribute to earlier detection and treatment.
How common are desmoid tumors?
Desmoid tumors are rare, affecting only a small percentage of the population. Despite being non-metastatic, they can be life-threatening due to aggressive local growth.
What treatment options are available for desmoid tumors?
Treatments include surgery, radiation therapy, hormonal therapy, NSAIDs, chemotherapy, and targeted therapies like tyrosine kinase inhibitors. Recently, new non-surgical therapies have gained popularity due to better outcomes.
Which region dominates the desmoid tumors market?
North America dominates due to strong healthcare infrastructure, high diagnosis rates, and ongoing clinical trials. Europe follows closely, while Asia-Pacific shows increasing growth potential.
What challenges does the market face?
Key challenges include limited awareness, high treatment costs, and delayed diagnosis. Variability in tumor behavior also makes treatment planning difficult.
What role does genetic testing play in desmoid tumors?
Genetic testing helps detect mutations such as CTNNB1 and APC, which are commonly associated with desmoid tumors. This information guides treatment decisions and prognosis.
How does early diagnosis affect treatment outcomes?
Early diagnosis improves treatment planning and reduces the risk of complications. It also allows for timely monitoring of tumor growth.
Which companies are major players in the desmoid tumor market?
Key players include SpringWorks Therapeutics, Bayer AG, AbbVie, Novartis AG, Ayala Pharmaceuticals, Iterion Therapeutics, and other biotech firms working on rare-disease therapies.
What opportunities exist in this market?
Opportunities include developing novel targeted therapies, expanding clinical trials in emerging regions, and improving diagnostic accuracy. Digital health monitoring tools also present new growth avenues.
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com